Press Releases

February 16, 2022 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
February 8, 2022 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO --(BUSINESS WIRE)--Feb. 8, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
January 25, 2022 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

Analysis of sera from Phase 1/2 booster study demonstrates 54- and 47-fold increases in geometric mean neutralizing antibody titers against the Omicron variant at Day 29 for ARCT-154 (5 mcg) and ARCT-165 (5 mcg) respectively SAN DIEGO --(BUSINESS WIRE)--Jan.

PDF Version
January 24, 2022 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants

Full cohort data from the ARCT-154 (5 mcg) arm of the ongoing Phase 1/2 booster study shows 30-fold increase in neutralizing antibody geometric mean concentrations against SARS-CoV-2 at Day 15 post-boost, maintained at 28-fold increase at Day 29, using a validated pseudovirus microneutralization

PDF Version
January 21, 2022 at 8:14 PM EST

Summary Toggle Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO --(BUSINESS WIRE)--Jan. 21, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
December 17, 2021 at 8:00 PM EST

Summary Toggle Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO --(BUSINESS WIRE)--Dec. 17, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
December 16, 2021 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials

Preliminary data from ongoing clinical booster study of ARCT-154 (5 mcg) shows a 50-fold increase in neutralizing antibody geometric mean concentration against SARS-CoV-2 using a validated pseudovirus microneutralization (MNT) assay Additional data shows activity against several variants of concern

PDF Version
December 13, 2021 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors

SAN DIEGO --(BUSINESS WIRE)--Dec. 13, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
November 22, 2021 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

SAN DIEGO --(BUSINESS WIRE)--Nov. 22, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
November 18, 2021 at 8:00 PM EST

Summary Toggle Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version